Simultaneous Isolation of Human Bone Marrow Hematopoietic, Endothelial, and Mesenchymal Progenitor Cells by Flow Sorting Based on Aldehyde Dehydrogenase Activity.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3651-3651
Author(s):  
Tracy Gentry ◽  
Sandra J. Foster ◽  
Lisa Winstead ◽  
Erica Deibert ◽  
Michelle Fiordalisi ◽  
...  

Abstract ALDH bright [ALDHbr] cells exhibit low side scatter and high activity of the intracellular enzyme aldehyde dehydrogenase [ALDH] in flow cytometric analysis. ALDH regulates gene expression in many developing systems by producing retinoic acids. ALDHbr populations from human umbilical cord [UCB] and mobilized peripheral blood preparations [PBSC] are highly enriched for cells that express CD34 and CD133 and for hematopoeitic progenitor cells. Because human bone marrow [BM] contains a highly heterogeneous population of stem and progenitor cells, we used multiparameter flow analysis and cell sorting to measure expression of cell surface markers and lineage specific developmental potential of BM ALDHbr populations. The ALDHbr population comprised 1.2 ± 0.8% (mean ± SD, n=39) of the nucleated BM cells and was significantly (p<0.05) enriched in cells expressing CD34, CD117, CD105, CD127, CD133, and CD166. ALDHbr populations were also significantly enriched in cells expressing primitive progenitor phenotypes including CD34+CD38− and CD34+CD133+ cells. The cell surface antigen expression of BM ALDHbr populations differed significantly from UCB and PBSC populations. In particular, the BM ALDHbr populations had more CD34− cells and CD45− cells and fewer CD133+ cells than the UCB and PBSC ALDHbr populations. Next, we compared the ability of sorted ALDHbr cells and ALDHdim cells derived from each bone marrow to develop into erythroid and myeloid cells, megakaryocytes, endothelial cells, and mesenchymal cells in culture. The ALDHdim population was the residual cell population produced when we sorted ALDHbr cells out of BM. ALDHbr populations were 144-fold more active in primary hematopoietic colony forming activity than ALDHdim cells, and all detectable BM cells that could form megakaryocyte colonies were ALDHbr. Even though hematopoietic progenitor activity was concentrated in the ALDHbr population, the majority of CD34+ and CD133+ cells in BM were ALDHdim. Cultures seeded with 50,000 ALDHbr cells gave rise to confluent growth of endothelial cells that expressed surface Ulex lectin receptors and von Willebrand factor, formed tubules on Matrigel, and took up acetylated LDL in 34 of 39 BM tested. In contrast, only 18 of 33 ALDHdim BM populations tested gave rise to endothelial cultures, and 500,000 ALDHdim cells were required to generate confluent cultures in 21 days. Cells that gave rise to early endothelial growth colonies at day 7 were 435-fold more frequent in the ALDHbr than the ALDHdim population. Confluent cultures of cells expressing cell surface antigens and functional attributes of multipotential mesenchymal cells were also routinely established with 50,000 ALDHbr cells. Again, ten-fold more ALDHdim cells than ALDHbr cells were needed to establish mesenchymal cultures. The mesenchymal cultures could be driven to differentiate into adipocytes, chondrocytes, osteoblasts, and neural lineage cells in standard culture assays. These results show that most of the hematopoietic, endothelial, and mesenchymal progenitor cell activities in human BM can be simultaneously isolated by cell sorting based on ALDH activity. Such ALDHbr populations may be useful in a variety of cell therapy indications.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4160-4160
Author(s):  
Ling Chen ◽  
Stephanie Jean-Noel ◽  
Kevin Hall ◽  
Ying Shi ◽  
Griffin P. Rodgers

Abstract The cell surface antigen, CD133, marks a fraction of hematopoietic stem and progenitor cells and has been successfully used to study their differential biology. To evaluate the differentiating capacity of stem/progenitor cells, we cultivated purified normal human bone marrow CD133 selected cells for 2 weeks with erythropoietin (EPO) or granulocyte colony-stimulating factor (G-CSF) to induce erythroid or myeloid differentiation, respectively. After the second week of cultivation, we reversed the seeding environment of the two populations by placing EPO treated cells into a G-CSF environment and G-CSF treated cells into an EPO environment for an additional 2-week culture. The cells produced in the culture were phenotypically defined by morphology and flow cytometry, and genotypically by RNA and proteomic analyses. Three-color flow cytometry was used for identifying CD133+ progenitors, CD36+ erythroid and CD13+ myeloid cells, as shown in Table 1. The morphology of the cultured cells, assessed by Wright-Giemsa staining, is consistent with the conversion of cellular specific markers. Rapid analysis of gene expression demonstrated co-expression of 76% of 266 genes analyzed among the erythroid and myeloid lineages. Furthermore, proteomic analysis exhibited the sharing of 33% of 9518 expressed protein spots assayed in the two populations after the first 2-week culture, and 32% after 2 weeks of the switch culture. Our data clearly demonstrate that the committed erythroid and myeloid precursors are able to change their fate and can switch into the opposite cell type by a conversion pathway under a specifically defined condition. We termed this switch as interconversion, considering conversion of hematopoietic cells to non-hematopoietic cells. Furthermore, the observations presented in this study show that cytokines used can improve the conversion. We are developing a mathematical model describing the kinetics of hematopoietic stem/progenitor cell transitions into specific lineages, along with the conversion of committed cells based on multiple potential energy wells corresponding to different cell states and cytokines. Table 1. Expression of cell surface markers after 4-week culture D0 1 week 2 weeks 4 weeks CD expression (%) E G E G E2w →G2w → G2w E2w Data are presented as a mean of at least 2 experiments. E: EPO; G: G-CSF; E2w or G2w: EPO or G-CSF treatment for two weeks. CD133+ 96.19 15.74 13.6 0.24 0.36 0.01 0.63 CD36+ 0 60.37 27.39 96.37 25.87 45.41 68.54 CD13+ 0.43 35.41 57.29 24.41 92.1 85.87 37.76 CD133+ / CD36+ 0.44 22.24 15.97 0.12 0.18 1.55 7.65 CD133+ / CD13+ 1.24 19.43 13.36 0.36 1.09 13.31 14.92 CD36+ / CD13+ 0.09 41.25 17.80 23.69 54.1 46.60 79.41


1999 ◽  
Vol 8 (2) ◽  
pp. 189-198 ◽  
Author(s):  
Robert E. Pyatt ◽  
Laura L. Jenski ◽  
Ruth Allen ◽  
Ken Cornetta ◽  
Rafat Abonour ◽  
...  

2012 ◽  
Vol 7 (6) ◽  
pp. 757-767 ◽  
Author(s):  
Sarah L Boddy ◽  
Wei Chen ◽  
Ricardo Romero-Guevara ◽  
Lucksy Kottam ◽  
Illaria Bellantuono ◽  
...  

2006 ◽  
Vol 34 (10) ◽  
pp. 1353-1359 ◽  
Author(s):  
Raquel Gonçalves ◽  
Cláudia Lobato da Silva ◽  
Joaquim M.S. Cabral ◽  
Esmail D. Zanjani ◽  
Graça Almeida-Porada

1992 ◽  
Vol 30 (4) ◽  
pp. 559-560
Author(s):  
R. DE BOCK ◽  
D. VAN BOCKSTAELE ◽  
H. SNOECK ◽  
F. LARDON ◽  
M. PEETERMANS

2000 ◽  
Vol 30 (7) ◽  
pp. 618-629 ◽  
Author(s):  
Rood ◽  
Calafat ◽  
Kr. Von dem Borne ◽  
Gerritsen ◽  
Van Der Schoot

1988 ◽  
Vol 54 (4) ◽  
pp. 593-600 ◽  
Author(s):  
A. Petkau ◽  
M.D. Sargent ◽  
W.S. Chelack ◽  
J.M. Gerrard

2021 ◽  
Vol 41 ◽  
pp. 603-615
Author(s):  
A-N Zeller ◽  
◽  
M Selle ◽  
Z Gong ◽  
M Winkelmann ◽  
...  

Underlying pathomechanisms of osteoporosis are still not fully elucidated. Cell-based therapy approaches pose new possibilities to treat osteoporosis and its complications. The aim of this study was to quantify differences in human bone marrow-derived mesenchymal stem cells (hBMSCs) between healthy donors and those suffering from clinically manifest osteoporosis. Cell samples of seven donors for each group were selected retrospectively from the hBMSC cell bank of the Trauma Department of Hannover Medical School. Cells were evaluated for their adipogenic, osteogenic and chondrogenic differentiation potential, for their proliferation potential and expression of surface antigens. Furthermore, a RT2 Osteoporosis Profiler PCR array, as well as quantitative real-time PCR were carried out to evaluate changes in gene expression. Cultivated hBMSCs from osteoporotic donors showed significantly lower cell surface expression of CD274 (4.98 % ± 2.38 %) than those from the control group (26.03 % ± 13.39 %; p = 0.007), as assessed by flow cytometry. In osteoporotic patients, genes involved in inhibition of the anabolic WNT signalling pathway and those associated with stimulation of bone resorption were significantly upregulated. Apart from these changes, no significant differences were found for the other cell surface antigens, adipogenic, osteogenic and chondrogenic differentiation ability as well as proliferation potential. These findings supported the theory of an influence of CD274 on the regulation of bone metabolism. CD274 might be a promising target for further investigations of the pathogenesis of osteoporosis and of cell-based therapies involving MSCs.


Sign in / Sign up

Export Citation Format

Share Document